Incidence and Classification of Postcolonoscopy Colorectal Cancers in Inflammatory Bowel Disease: A Dutch Population-Based Cohort Study

Wintjens, Dion S J; Bogie, Roel; Heuvel, Tim R A van den; Clercq, Chantal M. C. le; Oostenbrug, Liekele E.; Romberg‐Camps, Mariëlle; Straathof, Jan-Willem; Stassen, Laurents P. S.; Masclee, Ad; Jonkers, Daisy; Sanduleanu‐Dascalescu, Silvia; Pierik, Marie J.

doi:10.1093/ecco-jcc/jjy044

Cited by 26 publications

(24 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…colonoscopy until their last surveillance colonoscopy, colectomy, or CRC diagnosis, and estimated an incidence rate of 0.7 per 1000 years of follow-up [19]. Similarly, Wintjens et al reported a low PCCRC incidence rate of 0.39 per 1000 years of follow-up among 2801 IBD patients from the Netherlands [16]. Despite different PCCRC definitions, our CIPs are in line with those previously reported.…”

Section: Discussionsupporting

confidence: 88%

“…confirmed these findings [14]. It has been suggested that the elevated 3-year PCCRC rates in IBD patients stem from an increased likelihood of overlooking CRC and precancerous polyps, from aggressive biology leading to rapid CRC development, or are due to poor adherence to colonoscopy surveillance [16,17]. However, other explanations are possible.…”

mentioning

confidence: 71%

“…A UK study confirmed these findings [14]. It has been suggested that the elevated PCCRC-3 year rates in IBD patients stem from an increased likelihood of overlooking CRC and precancerous polyps, from aggressive biology leading to rapid CRC development or due to poor adherence to colonoscopy surveillance [16,17]. However, other explanations are possible: The PCCRC-3 year rate reflects the proportion of PCCRC among all CRCs diagnosed without taking into account the total number of patients undergoing colonoscopy, or each patient's cumulative number of colonoscopies.…”

Section: Introductionmentioning

confidence: 80%

“…Currently, only three studies have estimated the absolute risks of PCCRC, with incidence rates ranging from 0.39 to 2.5 per 1000 years of follow-up [16,19,20]. However, these studies were restricted to IBD patients undergoing surveillance colonoscopies.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Risk of a post-colonoscopy colorectal cancer diagnosis in patients with inflammatory bowel disease: a population-based cohort study

et al. 2020

View full text Add to dashboard Cite

Background and study aims: Post-colonoscopy colorectal cancers (PCCRCs) may account for up to 50% of all colorectal cancers (CRCs) diagnosed in patients with inflammatory bowel disease (IBD). This may reflect a high colonoscopy frequency; however evidence remains limited. Patient and methods: We conducted a cohort study of IBD and non-IBD patients undergoing colonoscopy. We calculated 6-36 months CIPs of PCCRC after first-time and subsequent colonoscopies. We also computed crude and adjusted HRs of PCCRC, comparing IBD with non-IBD patients undergoing first-time and subsequent colonoscopies. Separate analyses were conducted for consecutive colonoscopies. We calculated PCCRC-3 year rates to estimate the proportion of IBD and non-IBD CRC patients experiencing PCCRC. Results: We observed 138 and 1,909 PCCRCs among 34,688 IBD and 358,217 non-IBD patients who underwent colonoscopy. The CIP of PCCRC after first-time colonoscopy was 0.21%, 95% confidence interval (CI): [0.17-0.27] for IBD patients and 0.37%, 95% CI: [0.35-0.39] for non-IBD patients. The adjusted HR of PCCRC after a first-time colonoscopy was 0.96, 95% CI: [0.75-1.22] and the adjusted HRs after subsequent colonoscopies had point estimates around 1.0. The PCCRC-3 year rate was 24.3%, 95% CI: [20.4-28.7] for IBD and 7.5%, 95% CI [7.2-7.8] for non-IBD patients. Conclusions: Although PCCRCs accounted for a substantial proportion of all IBD-related CRCs, IBD patients had a low CIP of PCCRC after colonoscopy. The elevated PCCRC-3 year rates may among other factors stem from increased colonoscopy frequency in IBD patients.

show abstract

Section: Discussionsupporting

confidence: 88%

mentioning

confidence: 71%

Section: Introductionmentioning

confidence: 80%

mentioning

confidence: 99%

See 2 more Smart Citations

Risk of a post-colonoscopy colorectal cancer diagnosis in patients with inflammatory bowel disease: a population-based cohort study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These data, along with our findings, suggest that VLCDCA 28:4 is maintained at a homeostatic level in the bloodstream and that decrements in the levels of this anti-inflammatory lipid can result in the development of CRC. Inflammation plays an important role in the development of malignancies, such that Inflammatory Bowel Disease (IBD) [14] and Irritable Bowel Syndrome (IBS) [15], are associated with an increased risk of developing CRC, while aspirin [16] and non-aspirin NSAIDs [17] have been shown to decrease the risk of developing CRC. However, the CRC patient population is an heterogeneous group, since CRC can develop via different biochemical pathways.…”

Section: Discussionmentioning

confidence: 99%

Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts

et al. 2018

View full text Add to dashboard Cite

Background: There are currently no blood-based biomarkers for early diagnosis of colorectal cancer. Previous research has suggested that very-long-chain dicarboxylic acid (VLCDCA) 28:4 might be such a biomarker. Methods: Using high-resolution mass spectrometry, we analyzed VLCDCA 28:4 in the plasma of colorectal cancer patients in Italian [n = 62] and Brazilian [n = 52] cohorts. Additionally, we investigated individuals diagnosed with familial adenomatous polyposis (FAP; n = 27), one of the most important clinical forms of inherited susceptibility to colorectal cancer. Results: Decrements in plasma levels of VLCDCA 28:4 were monitored in colorectal cancer patients. These decreases were independent of the stage of tumor development and the individual’s age. However, no decrements in VLCDCA 28:4 were monitored in FAP patients. Conclusions: The plasma levels of VLCDCA 28:4 represent a potential biomarker of sporadic colorectal cancer. In addition, it is possible that resupply of this anti-inflammatory lipid may represent a new therapeutic strategy for CRC and inflammatory disorders.

show abstract

Chronische buikpijn

Horst¹,

Muris²,

Masclee³

2021

Diagnostiek Van Alledaagse Klachten

View full text Add to dashboard Cite

Incidence and Classification of Postcolonoscopy Colorectal Cancers in Inflammatory Bowel Disease: A Dutch Population-Based Cohort Study

Cited by 26 publications

References 31 publications

Risk of a post-colonoscopy colorectal cancer diagnosis in patients with inflammatory bowel disease: a population-based cohort study

Risk of a post-colonoscopy colorectal cancer diagnosis in patients with inflammatory bowel disease: a population-based cohort study

Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts

Chronische buikpijn

Contact Info

Product

Resources

About